CLRB - Cellectar Biosciences inks collaboration agreement with South Korea's LegoChemBio

subjob/iStock via Getty Images Cellectar Biosciences ("CLRB") has signed an agreement with South Korea's LegoChemBio to collaborate on the development and commercialization of first-in-class phospholipid drug conjugates ("PDCs"). Under the deal, both companies have the option to jointly develop three new small molecule PDCs utilizing Cellectar's proprietary drug targeting platform, phospholipid ether technology and LegoChemBio’s proprietary drug conjugate linker-toxin platform. Financial terms were not disclosed. Cellectar is focused on developing cancer treatments.

For further details see:

Cellectar Biosciences inks collaboration agreement with South Korea's LegoChemBio